PMID- 8591849
OWN - NLM
STAT- MEDLINE
DCOM- 19960403
LR  - 20111117
IS  - 0270-9139 (Print)
IS  - 0270-9139 (Linking)
VI  - 23
IP  - 2
DP  - 1996 Feb
TI  - Liver regeneration in fulminant hepatitis as evaluated by serum transforming 
      growth factor alpha levels.
PG  - 253-7
AB  - Transforming growth factor alpha (TGF alpha) is supposed to act as a mitogen for 
      hepatocytes in an autocrine manner in vitro and in vivo. Retarded liver 
      regeneration is a possible reason for poor prognosis of fulminant hepatitis (FH). 
      We analyzed serum TGF alpha levels in patients with FH and patients with acute 
      nonfulminant hepatitis (AH). Also, the relation of those levels to serum 
      hepatocyte growth factor (HGF) levels and their changes after glucagon-insulin 
      (G-I) therapy were studied. Maximal serum TGF alpha levels achieved in each case 
      after admission until recovery from disease or death were correlated positively 
      with maximal serum alanine transaminase (ALT) and total bilirubin levels in 
      patients with AH, but negatively with maximal total bilirubin levels in patients 
      with FH. Maximal serum TGF alpha levels in patients with FH were significantly 
      higher in survivors than in nonsurvivors. Maximal serum HGF levels were 
      positively correlated with maximal serum TGF alpha levels in patients with AH, 
      but not in patients with FH. Multiple regression analysis indicated that G-I 
      therapy was related to the increment of serum TGF alpha levels in patients with 
      FH. These results suggest that serum TGF alpha levels are increased in accordance 
      with liver regeneration after necrosis in patients with AH, but such liver 
      regeneration may be retarded, depending on the extent of liver damage in patients 
      with FH. G-I therapy seems to stimulate liver regeneration after liver damage. 
      The possible contribution of TGF alpha and HGF to liver regeneration merits 
      consideration for recovery from AH.
FAU - Tomiya, T
AU  - Tomiya T
AD  - First Department of Internal Medicine, Faculty of Medicine, University of Tokyo, 
      Japan.
FAU - Fujiwara, K
AU  - Fujiwara K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Hepatology
JT  - Hepatology (Baltimore, Md.)
JID - 8302946
RN  - 0 (Insulin)
RN  - 0 (Transforming Growth Factor alpha)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - 9007-92-5 (Glucagon)
SB  - IM
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glucagon/therapeutic use
MH  - Hepatitis/blood/drug therapy/*physiopathology
MH  - Hepatocyte Growth Factor/blood
MH  - Humans
MH  - Insulin/therapeutic use
MH  - *Liver Regeneration
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Regression Analysis
MH  - Transforming Growth Factor alpha/*blood
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
AID - S0270-9139(96)00042-0 [pii]
AID - 10.1053/jhep.1996.v23.pm0008591849 [doi]
PST - ppublish
SO  - Hepatology. 1996 Feb;23(2):253-7. doi: 10.1053/jhep.1996.v23.pm0008591849.